ADMA Biologics, headquartered in Ramsey, New Jersey, specializes in manufacturing FDA-approved plasma-derived biologics for immune deficiencies and infectious diseases, employing 624 staff. The company went public on October 17, 2013.
Steve Elms sold 194,749 shares of ADMA on 16 June at $20.24 per share, worth a total of $3.9M. They now own 87,330 ADMA shares, or a 69% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
